AU2001248365A1 - 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives - Google Patents

2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives

Info

Publication number
AU2001248365A1
AU2001248365A1 AU2001248365A AU4836501A AU2001248365A1 AU 2001248365 A1 AU2001248365 A1 AU 2001248365A1 AU 2001248365 A AU2001248365 A AU 2001248365A AU 4836501 A AU4836501 A AU 4836501A AU 2001248365 A1 AU2001248365 A1 AU 2001248365A1
Authority
AU
Australia
Prior art keywords
pyrimidone derivatives
heteroarylalkylamino
arylalkylamino
pyrimidone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248365A
Inventor
Antonio Almario Garcia
Ryoichi Ando
Keiichi Aritomo
Jonathan Reid Frost
Adrien Tak Li
Aya Shoda
Fumiaki Uehara
Kazutoshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Mitsubishi Pharma Corp
Original Assignee
Sanofi Synthelabo SA
Mitsubishi Tokyo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00400806A external-priority patent/EP1136491A1/en
Priority claimed from EP00400805A external-priority patent/EP1136099A1/en
Priority claimed from JP2000081938A external-priority patent/JP2001270884A/en
Priority claimed from EP00400804A external-priority patent/EP1136484A1/en
Application filed by Sanofi Synthelabo SA, Mitsubishi Tokyo Pharmaceuticals Inc filed Critical Sanofi Synthelabo SA
Publication of AU2001248365A1 publication Critical patent/AU2001248365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001248365A 2000-03-23 2001-03-22 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives Abandoned AU2001248365A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP00400805 2000-03-23
EP00400806A EP1136491A1 (en) 2000-03-23 2000-03-23 2-[(Heteroaryl)alkylamino]pyrimidone derivatives
EP00400805A EP1136099A1 (en) 2000-03-23 2000-03-23 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
EP00400806 2000-03-23
JP2000-81938 2000-03-23
JP2000081938A JP2001270884A (en) 2000-03-23 2000-03-23 Pyrimidone derivative
EP00400804 2000-03-23
EP00400804A EP1136484A1 (en) 2000-03-23 2000-03-23 2-(Arylalkylamino)pyrimidone derivatives
PCT/EP2001/003638 WO2001070727A1 (en) 2000-03-23 2001-03-22 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives

Publications (1)

Publication Number Publication Date
AU2001248365A1 true AU2001248365A1 (en) 2001-10-03

Family

ID=27440051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001248365A Abandoned AU2001248365A1 (en) 2000-03-23 2001-03-22 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives

Country Status (3)

Country Link
AR (1) AR028281A1 (en)
AU (1) AU2001248365A1 (en)
WO (1) WO2001070727A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284712T1 (en) 2000-04-26 2005-01-15 Eisai Co Ltd MEDICINAL COMPOSITIONS FOR PROMOTING VITAL ACTIVATION
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (en) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
EP1490093A4 (en) * 2002-03-01 2007-04-11 Novartis Vaccines & Diagnostic Methods and compositions for the treatment of ischemia
EP1616568A3 (en) * 2002-04-30 2006-06-21 Alcon, Inc GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents
EP1497420A4 (en) 2002-04-30 2005-04-27 Alcon Inc Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
JP2006506383A (en) 2002-10-21 2006-02-23 カイロン コーポレイション Inhibitor of glycogen synthase kinase 3
WO2005076854A2 (en) * 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
MX2007008326A (en) 2005-01-07 2008-01-16 Univ Emory Cxcr4 antagonists for the treatment of hiv infection.
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2041067A4 (en) * 2006-07-11 2009-11-25 Univ Emory Cxer4 antagonists including diazine and triazine structures for the treatment of medical disorders
CA2658263A1 (en) * 2006-07-18 2008-01-24 University Of Rochester Thiadiazolidinone derivatives
JP2010501540A (en) * 2006-08-23 2010-01-21 ファイザー・プロダクツ・インク Pyrimidone compounds as GSK-3 inhibitors
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
RU2536040C2 (en) * 2007-11-01 2014-12-20 Акусела Инк. Amine derivatives and their use for treatment of ophthalmological diseases and illnesses
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038955A1 (en) * 1996-12-05 2005-02-02 Amgen Inc PIRIMIDINONE AND PIRIDONA SUBSTITUTED COMPOUNDS AND METHODS FOR USE

Also Published As

Publication number Publication date
AR028281A1 (en) 2003-04-30
WO2001070727A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU2001248365A1 (en) 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
AU2001266583A1 (en) Epothilone derivatives and methods for making and using the same
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002226487A1 (en) Novel c-glycoside derivatives and use thereof
AU2001277754A1 (en) Proline derivatives and use thereof as drugs
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2001230338A1 (en) Isothiazole derivatives and their use as pesticides
AU2001281850A1 (en) Use of inulin and inulin derivatives
AU2001269175A1 (en) Diamino phenothiazine derivatives and composition comprising same
AU6124999A (en) Hydrazinooxoacetamide derivatives and insecticide
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001228667A1 (en) Isothiazole derivatives and their use as pesticides
AU2001248820A1 (en) Thiazole and oxazole derivatives
AU2001262149A1 (en) 2-(indanylamino)pyrimidone and 2-(tetrahydronaphthalenylamino)pyrimidone derivatives
AU7271600A (en) Quinazolinone and azaquinazolinone derivatives
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
AU2001230355A1 (en) Benzoxazole derivatives and their use as pesticides
AU2001230358A1 (en) Isothiazole derivatives and their use as pesticides
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2002219176A1 (en) Dihydroindole and tetrahydroquinoline derivatives
AU2002338989A1 (en) Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives